Figure 15.

Overexpression of FGF15 attenuated pathologic features inAtg5^Δheplivers. (A) Scheme of the FGF15 overexpression study in mouse livers. (B) Expression of ERK1/2 in the liver was analyzed by immunoblotting assay and quantified by densitometry. Phosphorylation levels of ERK1/2 were normalized to those of the total protein levels and expressed as fold change of GFP group (n = 8/group). (C) Hepatic expression of indicated genes was analyzed by qRT-PCR (n = 3–5/group). Data were expressed as fold change of GFP for the 1-week group. (D) TBA levels in the indicated compartments were measured (n = 3–5/group). (E) Serum levels of ALT, AST, ALP, and TBA in mice after AAV injection (n = 3–5/group). (F) Liver sections were subjected to H&E, anti-CK19, or Masson’s trichrome staining. Percentage of positive area was quantified with ImageJ (n = 3–5/group). Data are shown as means ± SE. ∗P < .05, ∗∗P < .01. AAV, adeno-associated virus; Bsep (Abcb11), bile salt export pump; Cyp7a1, cytochrome P450 7a1; GFP, green fluorescence protein.